4 days ago
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on scPharmaceuticals (SCPH – Research Report), 10x Genomics (TXG – Research Report) and Kura Oncology (KURA – Research Report).
Confident Investing Starts Here:
scPharmaceuticals (SCPH)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals on May 14 and set a price target of $11.00. The company's shares closed last Friday at $3.22.
According to Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 28.3% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $15.60 average price target, implying a 432.4% upside from current levels. In a report issued on May 12, Craig-Hallum also maintained a Buy rating on the stock.
10x Genomics (TXG)
In a report issued on May 14, Puneet Souda from Leerink Partners maintained a Hold rating on 10x Genomics. The company's shares closed last Friday at $9.39, close to its 52-week low of $8.92.
According to Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 29.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.
Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $12.56, a 36.2% upside from current levels. In a report issued on May 9, TD Cowen also maintained a Hold rating on the stock with a $11.00 price target.
Kura Oncology (KURA)
In a report issued on May 14, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology, with a price target of $23.00. The company's shares closed last Friday at $6.02.
According to Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.0% and a 28.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 279.2% upside from current levels. In a report issued on May 1, TD Cowen also maintained a Buy rating on the stock.
